Aim: It is to be elucidated the risk-predictive role of differentially expressed fatty acid metabolism related
genes (DE-FRGs) in dilated cardiomyopathy (DCM) and myocardial infarction. Materials & methods: Four
gene enrichment analyses defined DE-FRGs’ biological functions and pathways. Three strategies were
applied to identify risk biomarkers and construct a nomogram. The 4-DE-FRG correlation with immune
cell infiltration, drugs, and ceRNA was explored. Results: DE-FRGs were enriched in lipid metabolism. A
risk nomogram was established by ACSL1, ALDH2, CYP27A1 and PPARA, demonstrating a good ability for
DCM and myocardial infarction prediction. PPARA was positively correlated with adaptive immunocytes.
Thirty-five drugs are candidate therapeutic targets. Conclusion: A nomogram and new biological targets
for early diagnosis and treatment of DCM and myocardial infarction were provided.
Funding
This work was funded by the National Natural Science Foundation of China ( 82171698, 81300279, 81741067, 82170561), Project to Attract Foreign Experts from Minister of Science and Technology of China (G2022030047L), the Natural Science Foundation for Distinguished Young Scholars of Guangdong Province (2021B1515020003), famous overseas teachers from Science and Technology Department of Province (KD0120220129), national-level university students Innovative Training Program (202210570012), Natural Science Foundation of Guangdong Province (2022A1515012081), the Climbing Program of Introduced Talents and Highlevel Hospital Construction Project of Provincial People’s Hospital (KJ012019099, KJ012021143, KY012021183, DFJH201803), Guangdong Science and Technology Innovation Strategy Special Funds (pdjh2023b0429), Jointly funded by Guangzhou Municipal Bureau of Science and Technology for ‘Dengfeng Hospital’ project (SL2022A03J00586, SL2023A03J00586), Science and Technology Innovation Project for college students of Guangzhou Medical University (2021A028). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
